Key result
FMD virus-specific single-domain heavy-chain antibodies (VHHs) were successfully developed and utilized as capture antibodies in liquid-phase blocking ELISA, replacing rabbit coating antibodies.
May enable ethical alternatives to rabbit antibodies in FMD ELISA; leaves open validation across serotypes before routine adoption.
Foot-and-mouth disease (FMD) is an acute, highly contagious, and economically devastating viral disease of domestic and wildlife species. For effective implementation of FMD control program, there is an imperative need for developing a rapid, sensitive, and specific diagnostics which help in the identification of serotypes involved in the outbreaks. The humoral immune response of the Camelidae is unique since in these animals 75% of circulating antibodies are constituted by heavy-chain antibodies and 25% are conventional immunoglobulin with two identical heavy chains. In the present study, we developed and characterized FMD virus-specific single-domain heavy-chain antibodies (VHHs) against inactivated whole-virus antigens of FMDV serotypes O (INDR2/1975), A (IND40/2000), and Asia 1 (IND63/1972) vaccine strains. After six rounds of panning and enrichment, these VHHs were stably expressed in Escherichia coli cells. The VHHs directed against outer capsid proteins of FMD virus were successfully utilized as the capture antibody in liquid-phase blocking ELISA (LPBE) thus replacing rabbit coating antibodies. Our study demonstrated the utility of FMD virus-specific VHHs as potential candidates in FMD research and diagnostic application.
No takes yet. Share an insight, caveat, or question.
Dash et al. (2018) studied Foot-and-mouth disease. FMD virus-specific single-domain heavy-chain antibodies (VHHs) vs. Rabbit coating antibodies was evaluated on Utility as capture antibody in liquid-phase blocking ELISA (LPBE). FMD virus-specific single-domain heavy-chain antibodies (VHHs) were successfully developed and utilized as capture antibodies in liquid-phase blocking ELISA, replacing rabbit coating antibodies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: